Global innovation! Sansheng pharmaceutical is authorized by the new target of immunotherapy PSGL-1 mAb, reprogramming macrophages to stimulate synergistic antitumor response!

November 18, 2019 / BIOON / - sansbio pharmaceutical and Verseau therapeutics announced today that according to the cooperation agreement on the development and commercialization of innovative monoclonal antibodies for multiple cancers, the monoclonal antibody vtx-0811 targeting PSGL-1 has been selected as the first licensed product PSGL-1, as a new target of global innovative immunotherapy, can cause macrophage reprogramming and stimulate synergistic antitumor response Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of Sansheng pharmaceutical, will be responsible for the development and commercialization of vtx-0811 in mainland China, Taiwan, Hong Kong and Macau ("the region") By targeting PSGL-1, a highly expressed adhesion molecule on tumor associated macrophages, vtx-0811 reprogrammes macrophages into a pro-inflammatory state, activates T cells and attracts other immune cells to produce powerful antitumor effects In response to PD-1 and unresponsive tumors, Verseau's PSGL-1 antibody showed a stronger inflammatory response than the current immunotherapy PSGL-1 is the first target in the Verseau macrophage checkpoint regulator pipeline to enter the development stage Verseau's macrophage checkpoint regulator reprogrammes macrophages to make them more inflammatory or tolerable depending on the condition of the disease Under the terms of the agreement, Sansheng pharmaceutical will obtain an exclusive license in the region to develop and commercialize a series of macrophage checkpoint regulatory antibodies for all human tumor indications Verseau reserves the global interest in all macrophage checkpoint conditioning projects outside Greater China Verseau will be responsible for the early detection and optimization of macrophage checkpoint modulator antibody products Sansheng pharmaceutical will carry out preclinical and clinical development, product production, new drug registration and commercialization of macrophage checkpoint regulatory antibody in the region Verseau and Sansheng will be eligible for certain milestone payments and royalties for product sales in the region and globally The first joint development project selected under the partnership will result in a milestone payment for Verseau, the amount of which is not disclosed Dr Christine bunt, chief executive officer of Verseau, said: "we are very pleased to see the first licensing milestone in our cooperation with Sansheng pharmaceutical Sansheng pharmaceutical selected vtx-0811 as the first development project, which confirmed PSGL-1 as an important new target of immunooncology, and is expected to expand the potential of the number of patients benefiting from immunotherapy " "The innovative partnership with Sansheng pharmaceutical will help Verseau develop the industry-leading macrophage checkpoint regulator pipeline, which has first-class potential in many cancer treatment areas." Dr Lou Jing, chairman and chief executive officer of Sansheng pharmaceutical, said: "the early data of primary tumor from patient sources show that PSGL-1 antibody can produce stronger anti-tumor inflammatory response in response and non response tumors to PD-1 compared with current immunotherapy Through cooperation with Verseau, we have stepped into the forefront of the most promising innovation field in the field of immunooncology, and are gradually moving towards the goal of bringing new cancer therapies to Chinese patients We are looking forward to starting the development of the first project selected from this time, and also looking forward to selecting more new macrophage target projects from Verseau's all human transformation medical system in the future " PSGL-1 PSGL-1 (p- selectin glycoprotein ligand -1) is a kind of adhesion molecule, which is involved in immune cell metastasis caused by tissue injury or inflammation Verseau found that regulating PSGL-1 can lead to the reprogramming of macrophages The patented PSGL-1 monoclonal antibody can induce tumor microenvironment activation, T cell activation and initial immune cell recruitment, so as to carry out cooperative immune attack on tumor Primary tumor data from patients showed that PSGL-1 antibody showed stronger inflammatory response than current immunotherapy in PD-1 responsive and unresponsive tumors In view of the prominent role of PSGL-1 in various tumor treatments, Verseau chose PSGL-1 as the leading project of macrophage checkpoint modulator (MCM) for clinical development As for the macrophage checkpoint regulator Verseau, the potential of immunotherapy is being expanded through the development of macrophage checkpoint regulator (MCM), which can regulate the functional transformation of macrophages and make them more inflammatory or tolerant according to the specific conditions of the disease Although PD-1 inhibitor therapy benefits many patients, it is only effective for about 25% of patients with T cell infiltrated cancer Verseau's goal is to significantly expand the benefits of immunotherapy by regulating macrophages, which are present in about 75% of human cancers MCMs can cause tumor high inflammation and activate many immune cell types including T cells Versaeu's treatment has the potential to significantly increase the number of patients who benefit from immunotherapy, including those who do not respond to PD-1 inhibitors Through its proprietary all human transformation medical system, Verseau has verified more than 20 targets, which are suitable for different therapies including the use of monoclonal antibodies Sansheng Pharmaceutical Co., Ltd is a comprehensive biotechnology company, which has the market leading biopharmaceutical business, covering cancer, autoimmune disease, kidney disease, metabolic disease, skin disease and other treatment fields Sansheng pharmaceutical is committed to building an innovative product pipeline, and there are more than 30 candidate products under development Sansheng pharmaceutical has the ability to produce recombinant protein, monoclonal antibody and chemical synthetic molecular products It has R & D and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy Verseau is creating a new treatment, macrophage checkpoint regulator, that benefits patients with cancer, immune and inflammatory diseases Using Verseau's unique all human transformation medical system, we have identified new targets, and developed a therapy to make macrophages transform between immune activators and silencers in diseases Data show that this treatment can at least double the number of patients who benefit from immunotherapy Verseau's initial focus was to create a series of first-class therapies that regulate macrophages to trigger a synergistic immune attack on cancer Through its proprietary all human transformation medical system, Verseau has verified more than 20 targets, which are suitable for different therapies including the use of monoclonal antibodies Original source: Sansheng pharmaceutical